Search

Your search keyword '"Smolle, Maria"' showing total 509 results
Start Over Author "Smolle, Maria"
509 results on '"Smolle, Maria"'

20. Effect of radiotherapy on local recurrence, distant metastasis and overall survival in 1200 extremity soft tissue sarcoma patients. Retrospective analysis using IPTW-adjusted models

Author

Smolle, Maria A., Andreou, Dimosthenis, Wölfel, Judith, Acem, Ibtissam, Aj Van De Sande, Michiel, Jeys, Lee, Bonenkamp, Han, Pollock, Rob, Tunn, Per-Ulf, Haas, Rick, Posch, Florian, Van Ginkel, Robert J., Verhoef, Cornelis, Liegl-Atzwanger, Bernadette, Moustafa-Hubmer, Dalia, Jost, Philipp J., Leithner, Andreas, and Szkandera, Joanna

Published
2023
Full Text
View/download PDF

29. Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis

Author

Maisel, Franziska, Smolle, Maria A., Mollnar, Stefanie, Riedl, Jakob M., Barth, Dominik A., Seles, Maximilian, Terbuch, Angelika, Rossmann, Christopher H., Eisner, Florian, Mannweiler, Sebastian, Hutterer, Georg, Zigeuner, Richard, Pummer, Karl, Smolle-Jüttner, Freyja-Maria, Lindenmann, Jörg, Stotz, Michael, Gerger, Armin, Jost, Philipp J., Bauernhofer, Thomas, Pichler, Martin, and Posch, Florian

Published
2022
Full Text
View/download PDF

30. Precision medicine in diagnosis, prognosis, and disease monitoring of bone and soft tissue sarcomas using liquid biopsy: a systematic review.

Author

Smolle, Maria Anna, Seidel, Markus G., Kashofer, Karl, Liegl-Atzwanger, Bernadette, Sadoghi, Patrick, Müller, Daniel A., and Leithner, Andreas

Abstract

Introduction: Liquid biopsy as a non-invasive method to investigate cancer biology and monitor residual disease has gained significance in clinical practice over the years. Whilst its applicability in carcinomas is well established, the low incidence and heterogeneity of bone and soft tissue sarcomas explains the less well-established knowledge considering liquid biopsy in these highly malignant mesenchymal neoplasms. Materials and methods: A systematic literature review adhering to the PRISMA guidelines initially identified 920 studies, of whom 68 original articles could be finally included, all dealing with clinical applicability of liquid biopsy in sarcoma. Studies were discussed within two main chapters, i.e. translocation-associated and complex-karyotype sarcomas. Results: Overall, data on clinical applicability of liquid biopsy in 2636 patients with > 10 different entities of bone and soft tissue sarcomas could be summarised. The five most frequent tumour entities included osteosarcoma (n = 602), Ewing sarcoma (n = 384), gastrointestinal stromal tumour (GIST; n = 203), rhabdomyosarcoma (n = 193), and leiomyosarcoma (n = 145). Of 11 liquid biopsy analytes, largest evidence was present for ctDNA and cfDNA, investigated in 26 and 18 studies, respectively. Conclusions: This systematic literature review provides an extensive up-to-date overview about the current and potential future uses of different liquid biopsy modalities as diagnostic, prognostic, and disease monitoring markers in sarcoma. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

31. New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas.

Author

Joch, Sophie, Smolle, Maria Anna, Kashofer, Karl, Thüringer, Andrea, Szkandera, Joanna, Benesch, Martin, El-Heliebi, Amin, Liegl-Atzwanger, Bernadette, Leithner, Andreas, and Seidel, Markus G.

Subjects
*CIRCULATING tumor DNA, *DISEASE remission, *EARLY diagnosis, *DISEASE relapse, *TUMOR markers
Abstract

\nIntroduction: Assessment of circulating tumor DNA (ctDNA) as a means to monitor disease activity in translocation-associated tumors has become very popular in clinical practice. However, there are still few studies on its clinical application to date. Our study evaluates the clinical applicability of ctDNA as a biomarker for monitoring minimal residual disease (MRD) in patients with translocation-associated sarcomas. Methods: In this retrospective study, we correlated 285 ctDNA samples from 34 patients diagnosed with translocation-associated sarcoma with the clinical course and images. Blood samples were collected at multiple time points during follow-up (median: 97 weeks, range: 7–398). Results: We discovered a significant association between ctDNA levels and the clinical course of the disease, particularly noting differences between patients in remission or with progressive disease (p = 0.001). Furthermore, although we noted that ctDNA levels remained undetectable in a few cases of unilocular recurrence (n = 3), they were consistently higher in patients with multilocular recurrence (n = 14; p = 0.008). Conclusion: Monitoring ctDNA levels provides highly specific, additional information enabling early recurrence detection in patients with translocation-associated sarcomas during the follow-up and can be integrated into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques. This study investigates the emerging use of circulating tumor DNA (ctDNA) as a method to monitor the tumor burden in patients with a specific group of cancers called translocation-associated sarcomas. These rare cancers result from particular genetic changes called translocations. ctDNA is genetic material shed into the blood by tumor cells. Thus, ctDNA (with the tumor-specific translocation) detected in the blood of patients may represent a surrogate parameter for the presence of active tumor cells, serving as a genetic tumor marker. We analyzed 285 blood samples from 34 patients with translocation-associated sarcomas taken at different time points in the patients’ follow-up period of 7–398 weeks (2 years on average) to see how ctDNA levels correlated with the course of their disease. Our study found that ctDNA levels were strongly linked to a treatment response or recurrence of the disease. In tumor-free patients, ctDNA levels were undetectable. However, where the disease returned – especially if these levels were detectable in multiple areas – ctDNA levels went up again. In summary, using ctDNA analyses in translocation-associated cancers is a valuable, rather sensitive, and highly specific additional tool for monitoring the treatment response and for early detection of a recurring disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Proximal Fibula Resection for Tumors—Case Series and Technical Note.

Author

Hofer, Reinhard, Valentini, Marisa, Smolle, Maria Anna, Leithner, Andreas, and Bergovec, Marko

Subjects
KNEE joint, POSTEROLATERAL corner, PLASTIC surgery, COLLATERAL ligament, RANGE of motion of joints
Abstract

Background: The resection of tumors of the proximal fibula includes the removal of the lateral collateral ligament (LCL) and biceps femoris tendon (BFT) attachment. The aim was to describe and evaluate a surgical reconstruction technique in terms of functional outcome and knee joint stability. Methods: We analyzed the outcome of six patients, treated by a proximal fibula resection. The reconstruction of the attachments of the LCL and BFT was performed with two suture anchors, fixed onto the tibia at the level of the proximal tibiofibular joint (PTFJ). The postoperative knee flexion strength as well as the lateral knee joint stability were compared to the contralateral side using a digital scale and stress X-ray. Patient-reported outcome measures and postoperative complications were documented. Results: No lateral instability and no significant loss of knee flexion strength could be observed (p = 0.075). One persistent postoperative peroneus paresis was reported. High functional outcome was achieved with a mean MSTS score of 92.2%. Conclusions: The resection of the proximal fibula with the reinsertion of the LCL and the BFT using bone anchors in the PTFJ seems to provide a good functional outcome, with a low level of associated comorbidities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients

Author

Aston, Will, Bonenkamp, Han, Desar, Ingrid M.E., Ferguson, Peter C., Fiocco, Marta, Gelderblom, Hans, van Ginkel, Robert J., van der Graaf, Winette, Griffin, Anthony M., Haas, Rick L., van der Hage, Jos A., Hayes, Andrew J., Jeys, Lee M., Keller, Johnny, Laitinen, Minna K., Leithner, Andreas, Maretty-Kongstad, Katja, Ozaki, Toshifumi, Pollock, Rob, van Praag, Veroniek M., Smith, Myles J., Smolle, Maria A., Styring, Emelie, Szkandera, Joanna, Tanaka, Kazuhiro, Tunn, Per-Ulf, Willegger, Madeleine, Windhager, Reinard, Wunder, Jay S., Zaikova, Olga, Acem, Ibtissam, Verhoef, Cornelis, Rueten-Budde, Anja J., Grünhagen, Dirk J., van Houdt, Winan J., and van de Sande, Michiel A.J.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results